Last reviewed · How we verify
Bolus Remimazolam
At a glance
| Generic name | Bolus Remimazolam |
|---|---|
| Also known as | Bolus group |
| Sponsor | Second Affiliated Hospital of Wenzhou Medical University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- ED50 of Remimazolam for Anesthesia Induction in Frail Elderly Patients (NA)
- Sedation During Endoscopy Using Remimazolam: Efficacy in a Novel Exploration (PHASE3)
- The Efficacy of Remimazolam on Incidence of Hypoxia During Sedated Transvaginal Oocyte Retrieval: A Multicenter Randomized Controlled Trial. (NA)
- The Effect of Reversal of Remimazolam Sedation With Flumazenil on Cognitive Function in Patients Undergoing Hip Arthroplasty Under Spinal Anesthesia (PHASE4)
- The Effects of Remimazolam on Cerebral Blood Flow Following General Anesthesia Induction (PHASE4)
- Remimazolam vs Propofol in Laser Burn Cases (PHASE4)
- Remimazolam Infusion in Kidney Transplant Patients: A Multicenter Study (PHASE1)
- Varied Remimazolam Dosages for Pediatric Endoscopy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bolus Remimazolam CI brief — competitive landscape report
- Bolus Remimazolam updates RSS · CI watch RSS
- Second Affiliated Hospital of Wenzhou Medical University portfolio CI